3 fatty acid supplementation on arrhythmia recurrence in atrial fibrillatio

Completed

• Conditions: Cardiovascular disease/cardiac arrhythmias; Circulatory System; Atrial fibrillation and flutter

• Registration Number: ISRCTN52203885
• Lead Sponsor: Montreal Heart Institute (Institut de cardiologie de Montréal) (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06-30
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 332

Inclusion Criteria

1. Aged greater than or equal to 18 years, either sex
2. Written informed consent
3. Non-valvular paroxysmal or persistent AF in whom a rhythm control strategy is planned
4. Duration of at least one symptomatic AF episode greater than 10 minutes within the past 6 months
5. Electrocardiogram (ECG) documentation of AF
6. Left ventricular (LV) ejection fraction greater than 40%
7. Normal thyroid stimulating hormone (TSH)

Exclusion Criteria

1. Chronic AF (continuously present for greater than 3 months)
2. Myocardial infarction within the past month prior to selection visit
3. Cardiac or thoracic surgery within the past 3 months or likely to be performed during trial
4. Moderate to severe congestive heart failure (New York Heart Association Functional Class [NHYA FC] III - IV)
5. Left ventricular dysfunction (ejection fraction [EF] less than 40%)
6. Mitral stenosis
7. Moderate to severe mitral insufficiency (Grade 3 - 4/4)
8. AF secondary to an acute reversible condition (untreated or uncontrolled hyperthyroidism, post-operative AF, fever, anaemia)
9. Need for anti-arrhythmic therapy for a condition other than atrial fibrillation
10. Wolff-Parkinson-White syndrome
11. Any medical condition making compliance with study treatment unlikely
12. Current use of n-3 fatty acid supplements or use within the past 3 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified